Valneva Signs $39.6 Million IXIARO® Supply Contract with US Government
Valneva SE, a fully integrated, commercial stage bioteh company focused on developing innovative, lifesaving vaccines, announces today the signing of... View Article
Horama raises €19 million in a Series B financing round
A spin-off from Philippe Mouilier’s labratory at Nantes University Hospital, Horama has been supported by Atlanpole for 5 years .... View Article
VitamFero will be presenting its immunotherapy data about infection disease prevention in chicks
These groundbreaking findings highlight the prophylactic benefits of one of VitamFero non-virulent live parasitic strains for preventing opportunistic infections in... View Article
Boost4Health : Accelerate your internationalisation
Atlanpole Biotherapies, together with 10 other leading business support organisations in 7 countries, have joined forces to enable you to... View Article
VitamFero files 3 new patent applications
Moving forward with the development of its vaccine platform, and following the results achieved with its avian influenza vaccine candidate... View Article
Biomedical Tissues raises €500K for the marketing and commercialisation of its landmark product – Tisseos®
Biomedical Tissues, Atlanpole Biotherapies member and a medtech company, completed a €0.5 million capital increase over the summer. The funds... View Article
In-Cell-Art : Pass trough new steps for their Nanotaxi®
In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® designed to unlock the promise of nucleic acids to... View Article
Association of OSE Immunotherapeutics with GERCOR
OSE Immunotherapeutics Partners with Oncology Physician Network GERCOR to Conduct a Combination Phase 2 Trial of Tedopi® for Pancreatic Cancer.... View Article
ArronaxPlus [video]
ArronaxPlus presentation in video !
In-Cell-Art Announces Extension of a second Research Service Agreement with a Global Independent Vaccine Company
In-Cell-Art (ICA), a biotechnology company specializing in nanocarrier technologies named Nanotaxi® for unlocking the promise of nucleic acids to treat... View Article